2b ar primary antibody Search Results


anti nr2b  (Alomone Labs)
90
Alomone Labs anti nr2b
Anti Nr2b, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2b+ar+primary+antibody/Anti-NMDAR2B+(GluN2B)+(extracellular)-ATTO+Fluor-594+Antibody/pmc03658443-84-4-5
Average 90 stars, based on 1 article reviews
anti nr2b - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary mouse anti-vcan antibody clone 2-b-1  (Seikagaku corporation)
90
Seikagaku corporation primary mouse anti-vcan antibody clone 2-b-1
Representative examples of versican <t>(VCAN)</t> ( a , b , c ) and vascular endothelial growth <t>factor</t> <t>(VEGF)</t> ( d , e , f ) expression patterns and microvessel density (MVD) ( g , h , i ) in peritoneal lesions. The magnification is shown on the micrographs. Intensities were classified as negative, weak, moderate or strong. Scoring percentages of all markers are listed next. Stromal VCAN expression: negative (1.5 %), weak (28.4 %), moderate (32.8 %) and strong (37.3 %). Epithelial VCAN expression: negative (13.4 %), weak (14.9 %), moderate (26.9 %) and strong (44.8 %). VEGF expression: weak (11.9 %), moderate (43.3 %) and strong (44.8 %)
Primary Mouse Anti Vcan Antibody Clone 2 B 1, supplied by Seikagaku corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2b+ar+primary+antibody/primary+mouse+anti+vcan+antibody+clone+2+b+1/pmc04799792-119-11-16
Average 90 stars, based on 1 article reviews
primary mouse anti-vcan antibody clone 2-b-1 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary antibodies type 2b muscle ber  (Cloud-Clone corp)
90
Cloud-Clone corp primary antibodies type 2b muscle ber
Representative examples of versican <t>(VCAN)</t> ( a , b , c ) and vascular endothelial growth <t>factor</t> <t>(VEGF)</t> ( d , e , f ) expression patterns and microvessel density (MVD) ( g , h , i ) in peritoneal lesions. The magnification is shown on the micrographs. Intensities were classified as negative, weak, moderate or strong. Scoring percentages of all markers are listed next. Stromal VCAN expression: negative (1.5 %), weak (28.4 %), moderate (32.8 %) and strong (37.3 %). Epithelial VCAN expression: negative (13.4 %), weak (14.9 %), moderate (26.9 %) and strong (44.8 %). VEGF expression: weak (11.9 %), moderate (43.3 %) and strong (44.8 %)
Primary Antibodies Type 2b Muscle Ber, supplied by Cloud-Clone corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2b+ar+primary+antibody/primary+antibodies+type+2b+muscle+ber/ppr0287601-140-12-17
Average 90 stars, based on 1 article reviews
primary antibodies type 2b muscle ber - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mono/ polyclonal primary antibodies (mab, pab): mouse mab anti-psancam (clone 2-2b)  (Merck KGaA)
90
Merck KGaA mono/ polyclonal primary antibodies (mab, pab): mouse mab anti-psancam (clone 2-2b)
Representative examples of versican <t>(VCAN)</t> ( a , b , c ) and vascular endothelial growth <t>factor</t> <t>(VEGF)</t> ( d , e , f ) expression patterns and microvessel density (MVD) ( g , h , i ) in peritoneal lesions. The magnification is shown on the micrographs. Intensities were classified as negative, weak, moderate or strong. Scoring percentages of all markers are listed next. Stromal VCAN expression: negative (1.5 %), weak (28.4 %), moderate (32.8 %) and strong (37.3 %). Epithelial VCAN expression: negative (13.4 %), weak (14.9 %), moderate (26.9 %) and strong (44.8 %). VEGF expression: weak (11.9 %), moderate (43.3 %) and strong (44.8 %)
Mono/ Polyclonal Primary Antibodies (Mab, Pab): Mouse Mab Anti Psancam (Clone 2 2b), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2b+ar+primary+antibody/mono++polyclonal+primary+antibodies++mab++pab+++mouse+mab+anti+psancam++clone+2+2b+/pm28341445-55-0-11
Average 90 stars, based on 1 article reviews
mono/ polyclonal primary antibodies (mab, pab): mouse mab anti-psancam (clone 2-2b) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Representative examples of versican (VCAN) ( a , b , c ) and vascular endothelial growth factor (VEGF) ( d , e , f ) expression patterns and microvessel density (MVD) ( g , h , i ) in peritoneal lesions. The magnification is shown on the micrographs. Intensities were classified as negative, weak, moderate or strong. Scoring percentages of all markers are listed next. Stromal VCAN expression: negative (1.5 %), weak (28.4 %), moderate (32.8 %) and strong (37.3 %). Epithelial VCAN expression: negative (13.4 %), weak (14.9 %), moderate (26.9 %) and strong (44.8 %). VEGF expression: weak (11.9 %), moderate (43.3 %) and strong (44.8 %)

Journal: Clinical & Experimental Metastasis

Article Title: Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

doi: 10.1007/s10585-016-9779-9

Figure Lengend Snippet: Representative examples of versican (VCAN) ( a , b , c ) and vascular endothelial growth factor (VEGF) ( d , e , f ) expression patterns and microvessel density (MVD) ( g , h , i ) in peritoneal lesions. The magnification is shown on the micrographs. Intensities were classified as negative, weak, moderate or strong. Scoring percentages of all markers are listed next. Stromal VCAN expression: negative (1.5 %), weak (28.4 %), moderate (32.8 %) and strong (37.3 %). Epithelial VCAN expression: negative (13.4 %), weak (14.9 %), moderate (26.9 %) and strong (44.8 %). VEGF expression: weak (11.9 %), moderate (43.3 %) and strong (44.8 %)

Article Snippet: Sections were subsequently incubated overnight at 4 degrees Celsius with primary mouse anti-VCAN antibody (clone 2-B-1, Seikagaku, Tokyo, Japan; dilution 1:300) and anti-VEGF antibody labelling the VEGF-121, VEGF-165 and the VEGF-189 isoforms (clone v91, Dako, Carpinteria, USA, dilution 1:50) and incubated for 1 h at room temperature with anti-CD31 antibody (clone JC70A, Dako, Carpinteria, USA, dilution 1:50).

Techniques: Expressing

Final model resulting from multivariate survival analysis

Journal: Clinical & Experimental Metastasis

Article Title: Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

doi: 10.1007/s10585-016-9779-9

Figure Lengend Snippet: Final model resulting from multivariate survival analysis

Article Snippet: Sections were subsequently incubated overnight at 4 degrees Celsius with primary mouse anti-VCAN antibody (clone 2-B-1, Seikagaku, Tokyo, Japan; dilution 1:300) and anti-VEGF antibody labelling the VEGF-121, VEGF-165 and the VEGF-189 isoforms (clone v91, Dako, Carpinteria, USA, dilution 1:50) and incubated for 1 h at room temperature with anti-CD31 antibody (clone JC70A, Dako, Carpinteria, USA, dilution 1:50).

Techniques: Expressing

Significant associations between VCAN, VEGF, MVD and clinicopathological variables

Journal: Clinical & Experimental Metastasis

Article Title: Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

doi: 10.1007/s10585-016-9779-9

Figure Lengend Snippet: Significant associations between VCAN, VEGF, MVD and clinicopathological variables

Article Snippet: Sections were subsequently incubated overnight at 4 degrees Celsius with primary mouse anti-VCAN antibody (clone 2-B-1, Seikagaku, Tokyo, Japan; dilution 1:300) and anti-VEGF antibody labelling the VEGF-121, VEGF-165 and the VEGF-189 isoforms (clone v91, Dako, Carpinteria, USA, dilution 1:50) and incubated for 1 h at room temperature with anti-CD31 antibody (clone JC70A, Dako, Carpinteria, USA, dilution 1:50).

Techniques: Expressing

Kaplan–Meier curves of all patients. The graphs depict the curves according to the dichotomised vascular endothelial growth factor (VEGF) ( a ), microvessel density (MVD) ( b ), epithelial versican (VCAN) ( c ) and stromal VCAN ( d ) categories

Journal: Clinical & Experimental Metastasis

Article Title: Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

doi: 10.1007/s10585-016-9779-9

Figure Lengend Snippet: Kaplan–Meier curves of all patients. The graphs depict the curves according to the dichotomised vascular endothelial growth factor (VEGF) ( a ), microvessel density (MVD) ( b ), epithelial versican (VCAN) ( c ) and stromal VCAN ( d ) categories

Article Snippet: Sections were subsequently incubated overnight at 4 degrees Celsius with primary mouse anti-VCAN antibody (clone 2-B-1, Seikagaku, Tokyo, Japan; dilution 1:300) and anti-VEGF antibody labelling the VEGF-121, VEGF-165 and the VEGF-189 isoforms (clone v91, Dako, Carpinteria, USA, dilution 1:50) and incubated for 1 h at room temperature with anti-CD31 antibody (clone JC70A, Dako, Carpinteria, USA, dilution 1:50).

Techniques: